Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 24, 2018
4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD
LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (DDDD.L), a pharmaceutical company leading the development of live biotherapeutics, today announces positive ...
September 24, 2018
ProQR Announces Presentations at the OTS Annual Meeting
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA ...
September 24, 2018
MediWound Awarded Additional BARDA Contract Valued Up to $43 Million for Development of NexoBrid® for Sulfur Mustard Injuries
YAVNE, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe ...
September 24, 2018
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in ...
September 24, 2018
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi ...
September 24, 2018
AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
September 24, 2018
Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018
PALO ALTO, Calif., Sept. 24, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today ...
September 24, 2018
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) ...
September 24, 2018
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
September 24, 2018
STRATA Skin Sciences to Participate in Ladenburg Thalmann 2018 Healthcare Conference
HORSHAM, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
September 24, 2018
InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico
TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
September 24, 2018
Genocea to Present at Two October Investor Conferences
CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.(GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and ...
September 24, 2018
Acer Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
NEWTON, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
September 24, 2018
Albireo to Present at Cantor Fitzgerald Global Healthcare Conference
BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 24, 2018
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
DUBLIN, Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products for ...
September 24, 2018
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in ...
September 24, 2018
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
GAITHERSBURG, Md., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several ...
September 24, 2018
Transgene Unveils myvacTM, an Individualized Immunotherapy against Solid Tumors
Transgene (TNG.PA) (Euronext Paris: TNG) a biotechnology company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces myvacTM, an individualized, viral vector-based immunotherapy ...
September 24, 2018
Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced positive topline results from its Phase 2a trial of olorinab, an investigational, ...
September 24, 2018
Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
SANTA MONICA, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, ...
Page 38 of 138